Endocrine | 2021
Comparison of 68Ga-FAPI and 18F-FDG PET/CT in metastases of papillary thyroid carcinoma
Abstract
A 76-year-old woman presented with a 2-week history of dyspnea and hemoptysis. Previously, she had undergone a total thyroidectomy to treat papillary thyroid carcinoma previously. She then underwent a resection of the tracheal soft tissue nodule because of the risk of dyspnea. Histopathology of the biopsy from the tracheal nodule confirmed there was metastasis of the papillary thyroid carcinoma. Laboratory tests showed that her serum TG (244 ng/mL) was abnormally high, while a I whole-body scan was negative. She underwent F-FDG PET/CT to exclude possible recurrence and metastasis. F-FDG PET/CT detects pulmonary lesions and mediastinal lymph nodes very well, but is ambiguous for lesions in the liver, bone and abdominal lymph nodes. For further evaluation, the patient was enrolled in the clinical trial of Ga-FAPI PET/ CT in solid tumours approved by the institutional review board of our hospital, and written informed consent was obtained from the patient. Fibroblast activation protein (FAP) is highly expressed in many carcinomas [1], and Ga-FAPI is a promising PET tracer that can detect various primary tumors and metastases [1–3]. A previous study reported Ga-FAPI PET/CT showed better sensitivity than